Scancell Holdings plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SCLP.L | ATORX.ST | HURA | CHRS | MGNX | APLM | |
|---|---|---|---|---|---|---|
| Market cap | 116.66M | 38.54M | 109.61M | 131.36M | 147.15M | 55.38M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -370.6 | -0.1 | -2.8 | -1.3 | -1.6 | -29.2 |
| Price/book | -4.6 | 0.3 | 6.0 | 2.2 | 3.4 | -12.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −12.28% | −99.44% | −29.80% | −42.95% | +61.81% | +71.38% |
| Today | +1.16% | +0.93% | +3.93% | +5.54% | −0.86% | −8.83% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SCLP.L news ›Scancell cancer vaccine strategy backed by Moderna and Merck trial results
Panmure Liberum believes positive Phase 3 data for a cancer vaccine developed by Moderna and Merck supports the scientific rationale behind Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, and its…
Non-operating income (total) of SCANCELL HLDGS LS -,01 – FWB:SCP0
TradingView SCANCELL HLDGS LS -,01 Non-operating income (total) of SCANCELL HLDGS LS -,01
REG - Scancell Holdings - Result of General Meeting
(“Scancell”, the “Company” or the “Group”) Result of General Meeting Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the…
What do Scancell’s fresh results reveal about its next development stage (LSE:SCLP)?
Why is Sizewell C opening a new chapter for Hargreaves (LSE:HSP)? Why has Caledonia reset the outlook for Blanket (LSE:CMCL)? What is driving DF Capital’s next lending chapter (LSE:DFCH)? The preliminary financial information is unaudited,…
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of cancer immunotherapies, is pressing ahead with plans to list on the Nasdaq stock exchange following an all-share merger with US biotech Neuphoria Therapeutics,…
Scancell, Eco Buildings, ATOME, Caledonia Mining, Oxford Metrics - Small Cap Snapshot
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) is pressing ahead with a Nasdaq listing via its merger with Neuphoria. Shareholders vote on 20 October, with around $75 million of financing expected. Read more Eco Buildings Group PLC…
RNS Hotlist October 9: Roundhouse AI, Ajax, Seraphim Space Investment Trust, ECR Minerals, Mendell Helium, Georgina Energy, Amigo Resources, Scancell Holdings
Comment: The goal of RHAI is to become the Bloomberg of its chosen area, autonomous-agent activity. This is a punchy goal for a significant addressable market: $15tln. Ideally, it has the early, listed company advantage, and the expertise…
REG - Scancell Holdings - Preliminary Results
("Scancell", the "Company" or the "Group") Preliminary Results for the year ended 30 April 2026 Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- proactiveinvestors.com3
- tradingview.com3
- kalkinemedia.com1
- voxmarkets.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.